Table 2.
Comparison of patients depending on status and etiology of viral infection.
| Parameter | Non-Infected Patients (Controls) (n = 17) | Infected Patients (ADV or/and EBV Infection) (n = 10) | p-Value (Controls vs. ADV/EBV) | Patients with ADV Infection (n = 3) | p-Value (ADV Positive vs. ADV Negative Patients) | Patients with EBV Infection (n = 8) | p-Value (EBV Positive vs. EBV Negative Patients) |
|---|---|---|---|---|---|---|---|
| Percentage of women | 41.2% | 30.0% | >0.05 | 66.7% | >0.05 | 25.0% | >0.05 |
| Mean age (years) | 57.6 | 71.3 | 0.02 | 73.3 | >0.05 | 69.9 | >0.05 |
| Mean BMI (kg/m2) | 24.5 | 27.9 | 0.01 | 26.7 | >0.05 | 28.3 | 0.01 |
| Percentage of overweight patients (BMI > 25 kg/m2) | 41.2% | 80.0% | 0.0499 | 66.7% | >0.05 | 87.5% | 0.03 |
| Percentage of patients with diabetes | 11.8% | 50.0% | 0.02 | 33.3% | >0.05 | 62.5% | 0.006 |
| Percentage of patients with uncontrolled dyslipidemia | 41.2% | 10.0% | >0.05 | 0% | >0.05 | 12.5% | >0.05 |
| Median white blood cell count (k/uL) | 8.79 | 6.14 | >0.05 | 10.04 | >0.05 | 5.97 | 0.049 |
| Median hemoglobin concentration (g/dL) | 13.8 | 13.1 | >0.05 | 13.3 | >0.05 | 13.1 | >0.05 |
| Percentage of abnormal CRP values (>5 mg/L) | 23.5% | 30.0% | >0.05 | 66.7% | >0.05 | 12.5% | >0.05 |
| Median creatinine serum concentration (mg/dL) | 0.76 | 1.09 | 0.047 | 1.11 | >0.05 | 1.08 | >0.05 |
| Percentage of patients with chronic kidney disease (GFR < 60 mL/min/1.73 m2) | 29.4% | 70.0% | 0.04 | 100% | 0.04 | 62.5% | >0.05 |
| Percentage of patients with proteinuria (>30 mg/dL) | 23.5% | 20.0% | >0.05 | 33.3% | >0.05 | 12.5% | >0.05 |
| Percentage of patients with hematuria (>3 erythrocytes/HPF) | 41.2% | 50.0% | >0.05 | 66.7% | >0.05 | 50.0% | >0.05 |
| Percentage of patients with pyuria (>5 leukocytes/HPF) | 35.3% | 50.0% | >0.05 | 66.7% | >0.05 | 37.5% | >0.05 |
| Pathological stage of cancer | pT1a–58.8% pT1b–23.5% pT2a–5.9% pT2b–5.9% pT3a–5.9% pT3b-4–0% missing–0% |
pT1a–20% pT1b–20% pT2a–20% pT2b–10% pT3a–20% pT3b-4–0% missing–10% |
>0.05 | pT1a–0% pT1b–33.3% pT2a–33.3% pT2b–33.3% pT3a–0% pT3b-4–0% missing–0% |
>0.05 | pT1a–25.0% pT1b–12.5% pT2a–12.5% pT2b–12.5% pT3a–25.0% pT3b-4–0% missing–12.5% |
>0.05 |
| Histological grade of cancer | low grade–76.5% high grade–11.8% missing–11.8% |
low grade–40.0% high grade–60.0% missing–0% |
0.01 | low grade–33.3% high grade–66.7% |
>0.05 | low grade–37.5% high grade–62.5% |
0.02 |
| Histological RCC subtype | clear cell–76.5% papillary–5.9% chromophobe–17.6% other–0% |
clear cell–40.0% papillary–50.0% chromophobe–0% other–10.0% |
0.004 | clear cell–33.3% papillary–66.7% chromophobe–0% other–0% |
>0.05 | clear cell–50.0% papillary–37.5% chromophobe–0% other–12.5% |
>0.05 |
| Surgical procedure | partial nephrectomy–47.1% radical nephrectomy–52.9% |
partial nephrectomy–40.0% radical nephrectomy–60.0% |
>0.05 | partial nephrectomy–33.3% radical nephrectomy–66.7% |
>0.05 | partial nephrectomy–37.5% radical nephrectomy–62.5% |
>0.05 |
| 12-month cancer recurrence rate | 12.5% | 10.0% | >0.05 | 0% | >0.05 | 12.5% | >0.05 |